Micromyx is a microbiology services company specializing in anti-infective discovery and development for the pharmaceutical, biotechnology, and animal health industries. Founded in 2004 by former pharmaceutical industry infectious disease scientists, Micromyx is a unique contract research organization that offers clients documented, top of the line laboratory services from experts who have successfully gained FDA approval of new antibiotics.
Dr. Shinabarger has 16 years of antimicrobial discovery and development experience with Procter & Gamble Pharmaceuticals, Pharmacia Corporation and Micromyx. While at Pharmacia, Dr. Shinabarger was responsible for elucidating the mechanism of action and resistance of the antibiotic ZyvoxT, the first totally new antibiotic class approved in over 30 years. He was chosen to be a member of the ZyvoxT Development Team that presented this important new antibiotic to the FDA advisory committee in April 2000 and worked extensively with the Pharmacia marketing group to introduce ZyvoxT to physicians around the world. Dr. Shinabarger served as the team leader for discovering new antibiotics, managing a multidisciplinary team of 40 scientists. He also identified, contracted, and managed three important collaborations with academic researchers, and served on several teams that sought CROs for genomics and high-throughput screening projects. Dr. Shinabarger served as a member of the Pharmacia Research Leadership Team, contributing to the review and selection of compounds for drug development. In recognition of his scientific and leadership accomplishments, he was appointed to the Pharmacia Fellows Program in April 2000 and received a Special Recognition Award in 2003 for an important discovery in antibiotic research. At Micromyx, Dr. Shinabarger functions as Chief Executive Officer and continues to be actively engaged in antimicrobial research. Dr. Shinabarger has been invited to speak at several international meetings and is an author on 26 peer reviewed publications.
Microbiology Services, Microbial identification (Biochemical or 16S rRNA), Compound library and combinatorial library screening, Spectrum/potency assessments, Minimal Inhibitory Concentration (MIC) assay, Minimal Bactericidal Concentration (MBC) assay, Time-kill kinetic assays, Microbial quantitation, Resistance development/mutant selection, PCR detection of resistant genes, Assessment of serum protein effect on antimicrobial activity, Microbiome studies
DISCLAIMER: This Laboratory Profile was provided by the company above.